Oncology

News
MSD says subcutaneous Keytruda matches IV form

MSD says subcutaneous Keytruda matches IV form

A subcutaneous formulation of MSD's top-selling cancer immunotherapy, Keytruda, was non-inferior to the current intravenous version in a head-to-head trial, setting up regulatory filings.

Oncology
12 Questions with Gerhard du Toit
Sponsored

12 Questions with Gerhard du Toit

As Global Head of Oncology for IQVIA Biotech, Gerhard du Toit manages all aspects of oncology clinical trials, optimising strategies and enhancing delivery from early to late phases.